Inovio Pharmaceuticals, Inc. News (NASDAQ:INO)

DateTimeSource
Headline
09/12/20168:00AMGLOBEInovio’s Zika Vaccine Selected As 2016 Technology Breakthrough
PLYMOUTH MEETING, Pa., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its Zika vaccine in development has been named a 2016 Technology Breakthrough by the editors of Popular Mechanics magazine, the leading technology voice in the U.S. with millions of readers. Inovio has... More...>>
09/01/20169:05AMGLOBEInovio Pharmaceuticals to Present at Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will present a corporate overview at the following upcoming conferences: Citi 11th Annual Biotech ConferenceMandarin Oriental, Boston, Thursday, September 8th, 1x1 meetings 23rd Annual Newsmakers... More...>>
08/29/20167:00AMGLOBEInovio Launches Zika Vaccine Trial in Midst of Puerto Rico Epidemic to Explore Early Signals of Vaccine Efficacy
PLYMOUTH MEETING, Pa., Aug. 29, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced it has initiated a clinical study of its preventive Zika vaccine (GLS-5700) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency. The CDC estimates Zika... More...>>
08/16/20168:00AMGLOBEInovio Licenses Veterinary Foot and Mouth Disease Vaccine to Plumbline Life Sciences
PLYMOUTH MEETING, Pa., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced it has licensed a veterinary vaccine for foot and mouth disease (FMD) to Plumbline Life Sciences (KONEX: 222670), an animal health company headquartered in South Korea. Plumbline will fund all development... More...>>
08/11/20168:00AMGLOBEInovio Pharmaceuticals Expands Positive Phase I Ebola Vaccine Trial to Identify Most Optimal Immunization Regimen
PLYMOUTH MEETING, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the company is more than doubling study enrollment to further characterize and identify in humans the most optimal immunization regimen using intradermal (skin) delivery of its preventive Ebola DNA vaccine... More...>>
08/08/20167:30PMGLOBEGeneOne Life Science Announces Full Enrollment of First-In-Human Study of MERS Vaccine
SEOUL, South Korea, Aug. 08, 2016 (GLOBE NEWSWIRE) -- GeneOne Life Science Inc. (KSE:011000) today announced that enrollment has been completed of the first-in-human clinical trial of the GLS-5300 vaccine for MERS (Middle East Respiratory Syndrome) with a total of 75 subjects. GeneOne Life Science and U.S.-based Inovio... More...>>
08/08/20168:00AMGLOBEInovio Pharmaceuticals Reports 2016 Second Quarter Financial Results
PLYMOUTH MEETING, Pa., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended June 30, 2016. The following financial results provide a year-over-year comparison of the second quarter in 2016 and 2015. Total revenue was $6.2 million compared to... More...>>
08/04/20168:00AMGLOBEInovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs
PLYMOUTH MEETING, Pa., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the appointment of Dr. Ami Shah Brown as Vice President Regulatory Affairs. Dr. Brown, who joined Inovio in 2011 as Senior Director of Regulatory Affairs, will be responsible for developing and implementing... More...>>
08/03/20169:00AMGLOBEInovio will Independently Develop Hepatitis B Immunotherapy
PLYMOUTH MEETING, Pa., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the company will continue to develop its hepatitis B DNA immunotherapy (INO-1800) independently following Roche’s notice that it will discontinue its collaboration with Inovio and its development of INO-1800... More...>>
07/26/201610:28AMGLOBEInovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial
PLYMOUTH MEETING, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the dosing of the first subject in its multi-center phase I trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700). In addition to the previously announced US FDA approval for the conduct of the study, Health... More...>>
07/26/20168:00AMGLOBEInovio Pharmaceuticals to Report Second Quarter 2016 Financial Results August 8, 2016
PLYMOUTH MEETING, Pa., July 26, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to discuss its 2016 second quarter financial results and provide a corporate update on Monday, August 8, 2016 at 8:30 a.m. ET. A live and archived version... More...>>
07/14/20168:00AMGLOBEInovio Deploys DNA-based Monoclonal Antibody Technology in Quest to Cure HIV
PLYMOUTH MEETING, Pa., July 14, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its novel DNA-based monoclonal antibody technology will be deployed to develop products which could be used alone and in combination with other immunotherapies in the pursuit of new ways to treat and... More...>>
07/11/20168:23AMPRNUSBiotechnology Stocks Under the Scanner -- PTC Therapeutics, Inovio Pharma, VIVUS, and Spectrum Pharma
Biotechnology Stocks Under the Scanner -- PTC Therapeutics, Inovio Pharma, VIVUS, and Spectrum Pharma PR Newswire NEW YORK, July 11, 2016 NEW YORK, July 11, 2016 /PRNewswire/ -- On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40... More...>>
07/06/20161:40AMDJNSanofi Teams Up With U.S. Army on Zika Vaccine
Sanofi SA has formed a partnership with the U.S. Army to expand research and development of an experimental Zika vaccine that has shown promise in early laboratory studies and is among a few candidates expected to be tested on humans in the coming months. At least 15 companies and entities, including Sanofi, are racing... More...>>
06/20/20167:00AMGLOBEInovio Pharmaceuticals and GeneOne Life Science Receive Approval for First-in-Man Zika Vaccine Clinical Trial
PLYMOUTH MEETING, Pa. and SEOUL, South Korea, June 20, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and GeneOne Life Science, Inc. (KSE:011000) today announced that they have received approval to initiate a phase I human trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700) to prevent infection... More...>>
05/16/20168:00AMGLOBEInovio Pharmaceuticals Zika Vaccine Produces Robust Immune Responses in Non-Human Primates
PLYMOUTH MEETING, Pa., May 16, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that testing of its synthetic vaccine for the Zika virus induced robust antibody and T cell responses in non-human primates (monkeys), demonstrating the product’s potential to prevent infection from this... More...>>
05/11/20168:00AMGLOBEInovio Pharmaceuticals to Present at UBS Global Healthcare Conference
PLYMOUTH MEETING, Pa., May 11, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported that the Company will present a corporate overview at the UBS Global Healthcare Conference on Wednesday, May 25th at 8:30AM EDT. A live and archived version of presentation delivered by Inovio’s COO, Dr. Niranjan... More...>>
05/09/20167:50AMGLOBEInovio Pharmaceuticals Reports 2016 First Quarter Financial Results
PLYMOUTH MEETING, Pa., May 09, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended March 31, 2016. Total revenue was $8.1 million for the three months ended March 31, 2016, compared to $5.2 million for the same period in 2015. Total operating expenses... More...>>
05/04/20168:00AMGLOBEInovio Pharmaceuticals Showcases its Broad Pipeline of DNA-based Immunotherapies, Vaccines and dMAbs at the American Societ...
PLYMOUTH MEETING, Pa., May 04, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it will exhibit the breadth and promise of its cancer and infectious disease immunotherapy, vaccine and DNA-based monoclonal antibody (dMAb) pipeline in 10 presentations at the 19th Annual Meeting of the American... More...>>
05/02/20167:31AMGLOBEInovio Pharmaceuticals Completes Acquisition of Needle-Free Injection Technology
PLYMOUTH MEETING, Pa., May 02, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has closed the transaction to acquire all of BioJect Medical Technologies Inc.’s assets, including pioneering needle-free jet injection technology, devices, and intellectual property, which it first announced... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20160928 23:57:49